Skip to main content

Peer Review reports

From: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain

Original Submission
7 Feb 2017 Submitted Original manuscript
12 Jul 2017 Author responded Author comments - M Sanchez-Luna
10 Jun 2017 Reviewed Reviewer Report - Bernhard Resch
22 May 2017 Reviewed Reviewer Report - Leonard R Krilov
Resubmission - Version 2
12 Jul 2017 Submitted Manuscript version 2
21 Sep 2017 Author responded Author comments - M Sanchez-Luna
14 Jul 2017 Reviewed Reviewer Report - Bernhard Resch
13 Aug 2017 Reviewed Reviewer Report - Leonard R Krilov
Resubmission - Version 3
21 Sep 2017 Submitted Manuscript version 3
Publishing
6 Oct 2017 Editorially accepted
17 Oct 2017 Article published 10.1186/s12879-017-2803-0

You can find further information about peer review here.

Back to article page